Neurogene Inc. (NASDAQ:NGNE) Receives Consensus Rating of “Moderate Buy” from Analysts

Neurogene Inc. (NASDAQ:NGNE) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $42.50.

Several equities research analysts recently issued reports on the stock. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price target on shares of Neurogene in a research note on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research note on Wednesday, October 8th. Finally, Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a research report on Saturday, December 13th.

Neurogene Stock Down 3.6%

NASDAQ NGNE opened at $18.31 on Monday. Neurogene has a fifty-two week low of $6.88 and a fifty-two week high of $37.27. The business has a 50 day moving average price of $19.78 and a two-hundred day moving average price of $22.03. The stock has a market cap of $283.62 million, a PE ratio of -4.45 and a beta of 1.60.

Neurogene (NASDAQ:NGNE) last posted its earnings results on Thursday, November 13th. The company reported ($0.99) EPS for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.27. Sell-side analysts anticipate that Neurogene will post -4.27 EPS for the current fiscal year.

Hedge Funds Weigh In On Neurogene

Institutional investors have recently made changes to their positions in the business. Balyasny Asset Management L.P. acquired a new stake in shares of Neurogene during the third quarter worth approximately $12,114,000. ArrowMark Colorado Holdings LLC grew its holdings in Neurogene by 1.8% during the 3rd quarter. ArrowMark Colorado Holdings LLC now owns 595,839 shares of the company’s stock worth $10,326,000 after acquiring an additional 10,442 shares in the last quarter. Jennison Associates LLC increased its position in shares of Neurogene by 55.0% in the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock worth $2,505,000 after purchasing an additional 59,479 shares during the last quarter. Blair William & Co. IL raised its stake in shares of Neurogene by 6.4% in the 3rd quarter. Blair William & Co. IL now owns 141,820 shares of the company’s stock valued at $2,458,000 after purchasing an additional 8,584 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Neurogene by 81.6% in the 2nd quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock valued at $1,426,000 after purchasing an additional 42,880 shares in the last quarter. 52.37% of the stock is owned by institutional investors and hedge funds.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.